Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Search
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Exploring T-cells in cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop
Boehringer Ingelheim to unveil oncology research at WCLC
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio